Form 4: Matthew Pauls Reports Acquisition of Soleno Therapeutics Stock
SEC Form 4 Filing
Director Matthew Pauls acquired 6,500 shares of Soleno Therapeutics stock in the form of restricted stock units (RSUs) on June 6, 2024.
Summary
- On June 6, 2024, Matthew Pauls, a director of Soleno Therapeutics Inc., acquired 6,500 shares of common stock in the form of restricted stock units (RSUs).
- The RSUs vest on the earlier of June 6, 2025, or the day before the next annual stockholder meeting, contingent upon continued service.
- Pauls previously elected to defer receipt of shares upon vesting, with delivery occurring upon cessation of services or a change of control.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Future Outlook
The vested shares will be delivered to the Reporting Person when the Reporting Person ceases to provide services to the Issuer or upon a change of control of the Issuer.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of shares by a director can be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: Matthew Pauls acquired 6,500 shares of Soleno Therapeutics stock in the form of restricted stock units (RSUs). |
| 06/10/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.